GENE ONLINE|News &
Opinion
Blog

2025-11-29|

Study Explores How KaiXinSan Influences Serotonin and GABA Pathways to Address Insomnia

by GOAI
Share To

Researchers have identified potential mechanisms behind the herbal formulation KaiXinSan, which has been traditionally used to address insomnia. A recent study conducted by Zhang, S., Guo, D., and Zhao, C. utilized advanced methodologies to explore how this classical remedy may influence sleep regulation. The findings provide new insights into the biological processes associated with its use for treating sleep disorders.

The study examined the active compounds within KaiXinSan and their effects on neurological pathways linked to insomnia. Researchers analyzed its impact on neurotransmitter systems, including serotonin and gamma-aminobutyric acid (GABA), both of which play critical roles in regulating sleep patterns. The investigation also highlighted the potential anti-inflammatory and stress-reducing properties of the formulation, which may contribute to its reported efficacy in improving sleep quality. These findings mark a significant step forward in understanding how traditional herbal remedies interact with modern medical science.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top